Faculty

Ugur T. Sener, M.D.

Clinical Studies

MC230713 Neuro-Oncology Anywhere: Deploying Mayo Clinic’s remote cognitive assessment battery and wearable device monitoring platform while assessing the impact of metformin on cognition and quality of life in patients with history of cranial radiation (Neuro-Oncology Anywhere) Rochester, Minn.
The purpose of this study is to determine the feasibility of completing serial remote cognitive, activity/sleep, and selfreport assessments in clinical trial participants who have previously received cranial radiation.
Patient and caregiver priorities in neuro-oncology care Rochester, Minn.
The purpose of this study is to conduct semi-structured interviews with patients who have primary and metastatic CNS tumors as well as caregivers of these patients.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of Optune® (TTFields, 200 KHz) Concomitant With Maintenance Temozolomide And Pembrolizumab Versus Optune® Concomitant With Maintenance Temozolomide And Placebo For The Treatment Of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58). (EF-41) Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
MC240703 Neuro-Oncology Anywhere: Glioma Home-based Sequential Therapy (GHoST) Protocol (GHoST) Rochester, Minn.
The purpose of this study is to determine the feasibility of the remote chemotherapy management and patient monitoring platform GHoST Protocol among patients with glioma undergoing systemic therapy.

Neuro-Oncology Anywhere 242: Pilot Study Evaluating Telehealth and In-person Assessments in Patients with Glioma Receiving Oral Chemotherapy Rochester, Minn.
The purpose of this study is to evaluate the safety, feasibility and acceptability of telehealth assessments for patients with GBM receiving oral chemotherapy.